LATE-BREAKING ABSTRACT: Differences in S. pneumoniae serotypes distribution causing CAP in hospitalized adults in Spain according to comorbidities by a new urinary antigen detection (UAD) test. The CAPA study

Background and objective: The presence of underlying conditions increases the risk of CAP. The 13-valent pneumococcal conjugate vaccine (PCV13) has demonstrated efficacy in the prevention of pneumococcal pneumonia and invasive pneumococcal disease in adults. In order to assess the burden of CAP, including non-bacteremic CAP, due to PCV13 serotypes (St), we explored differences in the distribution of PCV13 St in immunocompetent patients u003e18 years hospitalized in 3 Spanish hospitals (November 2011-June 2014) by presence of underlying conditions. Methods: In subjects hospitalized with chest X-ray confirmed CAP, microbiological confirmation was sought by the novel UAD assay (Pfizer9s PCV13 serotype specific urinary antigen detection test), BinaxNOW u0026 conventional cultures. Serotyping of pneumococcal isolates was accomplished in a central laboratory using Quellung reaction. Results: S. pneumoniae CAP was confirmed in 351 (29.8%) of 1179 included patients. Underlying conditions and/or risk habits were present in 87.4% of patients (mean age 67.7±17.9). Below table shows PCV13 St distribution in CAP by presence of specific underlying conditions according to UAD test results. Conclusion: Among at risk adults with chronic diseases, more than 50% of pneumococcal CAP cases were due to PCV13 serotypes.